<p class="abstract"><strong>Background:</strong> Chlamydia infections in humans and animals pose a significant burden on health systems worldwide. While widespread screening, adequate treatment, and prevention programs are helpful to increase awareness and improve screening rates, infection rates are rising. A vaccine is necessary to slow increasing rates, manage negative consequences, and prevent possible antibiotic resistance. We present the current landscape regarding the innovations for commercial vaccine development in a “one-health” context.</p><p class="abstract"><strong>Methods:</strong> We developed a unique dataset containing data of patent documents intended for human and veterinary use, and clinical trials in order to provide a detailed description of the global chlamydia vaccine developments.</p><p class="abstract"><strong>Results:</strong> Analysis of patents and clinical trials intended for human use presented a vaccine field that is underdeveloped, with no commercial human chlamydia vaccine available, and two potential candidates in a phase 1 clinical trial. Comparing innovations concerning chlamydia vaccine developments for both human and veterinary patents, it was clear that these fields are very different and independent of each other. The field is small, and certain companies and researchers show repeated interest. Partnerships among applicants and those involved in chlamydia vaccine innovation would be an important step to take towards innovating and developing an effective vaccine.</p><p class="abstract"><strong>Conclusions: </strong>We have shown that North America is considered, by patent application, to hold the most potential for a chlamydia vaccine, specifically against the <em>Chlamydia trachomatis </em>strain. A new vaccine is likely to be a subunit vaccine with components of the major outer membrane protein antigen.</p>
(1) Despite its high prevalence, the diagnostic delay of endometriosis is still estimated to be about 7 years. The objective of the present study is to understand the symptomatology of endometriosis in patients across various countries and to assess whether the severity of symptoms correlates with the diagnosed stage of disease. (2) An international online survey collected self-reported responses from 2964 participants from 59 countries. Finalization of the questionnaire and its distribution was achieved by cooperation with various organizations and centers around the globe. (3) Chronic pain presentation remarkably increased between Stage 1 and 2 (16.2% and 32.2%, respectively). The prevalence of pain only around and during menstruation was negatively correlated to the stage, presenting with 15.4% and 6.9% in Stages 1 and 4, respectively. Atypical presentation of pain was most commonly reported in stage 4 (11.4%). Pain related solely to triggering factors was the most uncommon presentation of pain (3.2%). (4) Characteristics of pain and quality of life tend to differ depending on the reported stage of the endometriosis. Further research may allow a better stage estimation and identification of patients with alarming symptomatic presentation indicative of a progressive stage, even those that are not yet laparoscopically diagnosed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.